additional structure/function-related mediators that are designed to treat various diseases. NFAs are cell-signaling agents that regulate major inflammatory signaling pathways (e.g., Nrf2, NFkB, and HSF). Capitalizing on their identification and synthesis of these endogenous signaling mediators, Complexa's technologies act to amplify the existing anti-inflammatory and metabolic signaling mechanisms that promote the resolution and repair of acute and chronic tissue injury and disease.

It is headquartered in Berwyn, Pennsylvania.